EA202092576A1 - Антитела с модулированными гликановыми профилями - Google Patents

Антитела с модулированными гликановыми профилями

Info

Publication number
EA202092576A1
EA202092576A1 EA202092576A EA202092576A EA202092576A1 EA 202092576 A1 EA202092576 A1 EA 202092576A1 EA 202092576 A EA202092576 A EA 202092576A EA 202092576 A EA202092576 A EA 202092576A EA 202092576 A1 EA202092576 A1 EA 202092576A1
Authority
EA
Eurasian Patent Office
Prior art keywords
profiles
glycane
antibodies
modulated
denosumab molecules
Prior art date
Application number
EA202092576A
Other languages
English (en)
Inventor
Кристофер Кенион Кроуэлл
Цзянь У
Афина Дениз Наджи
Нил Энтони Китчен
Элисон Джин Гиллеспи
Симина Крина Петрован
Майкл Чарльз Бранденштейн
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA202092576A1 publication Critical patent/EA202092576A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к рекомбинантно экспрессируемым молекулам деносумаба и способам модулирования гликановых профилей молекул деносумаба.
EA202092576A 2018-05-01 2019-04-30 Антитела с модулированными гликановыми профилями EA202092576A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862665045P 2018-05-01 2018-05-01
PCT/US2019/029850 WO2019213043A1 (en) 2018-05-01 2019-04-30 Antibodies with modulated glycan profiles

Publications (1)

Publication Number Publication Date
EA202092576A1 true EA202092576A1 (ru) 2021-02-05

Family

ID=66542532

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092576A EA202092576A1 (ru) 2018-05-01 2019-04-30 Антитела с модулированными гликановыми профилями

Country Status (16)

Country Link
US (1) US20210062156A1 (ru)
EP (2) EP4316519A3 (ru)
JP (1) JP2021521854A (ru)
KR (1) KR20210005689A (ru)
CN (1) CN112074537A (ru)
AU (1) AU2019263008A1 (ru)
BR (1) BR112020022166A2 (ru)
CA (1) CA3099163A1 (ru)
CL (1) CL2020002810A1 (ru)
EA (1) EA202092576A1 (ru)
IL (2) IL278211B1 (ru)
MA (1) MA52490A (ru)
MX (1) MX2020011614A (ru)
SG (1) SG11202010744YA (ru)
TW (1) TW202003574A (ru)
WO (1) WO2019213043A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202405159A (zh) * 2022-06-28 2024-02-01 美商安進公司 用於治療性產品製造的靈活的設施配置
CN117825686A (zh) * 2024-03-05 2024-04-05 军科正源（北京）药物研究有限责任公司 用于检测地诺单抗抗药性抗体的样品预处理方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159259A (en) * 1875-02-02 Improvement in reservoir cooking-stoves
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2013181575A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
TWI625390B (zh) * 2013-03-14 2018-06-01 安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US8956830B2 (en) * 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2014318017B2 (en) * 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

Also Published As

Publication number Publication date
MX2020011614A (es) 2020-12-09
WO2019213043A1 (en) 2019-11-07
TW202003574A (zh) 2020-01-16
AU2019263008A1 (en) 2020-11-19
JP2021521854A (ja) 2021-08-30
EP3788076A1 (en) 2021-03-10
IL307155A (en) 2023-11-01
IL278211A (en) 2020-11-30
US20210062156A1 (en) 2021-03-04
CA3099163A1 (en) 2019-11-07
SG11202010744YA (en) 2020-11-27
CN112074537A (zh) 2020-12-11
KR20210005689A (ko) 2021-01-14
MA52490A (fr) 2021-03-10
EP4316519A3 (en) 2024-04-24
EP4316519A2 (en) 2024-02-07
CL2020002810A1 (es) 2021-02-19
IL278211B1 (en) 2023-10-01
BR112020022166A2 (pt) 2021-01-26

Similar Documents

Publication Publication Date Title
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
PH12019502283A1 (en) Anti-lag3 antibodies
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA202090812A1 (ru) Новые биспецифические полипептидные комплексы
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201892312A1 (ru) Триспецифические и/или тривалентные связывающие белки
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201692476A1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201890329A1 (ru) СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
EA201691589A1 (ru) Стабилизированные основанные на фибронектине каркасные молекулы
EA201992206A1 (ru) Моноклональное антитело к pd-l1
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
MX2019011585A (es) Anticuerpos miltiespecificos estables.
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA201991876A1 (ru) Антитела против фактора d и их применения
EA202092576A1 (ru) Антитела с модулированными гликановыми профилями
EA201892368A1 (ru) ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
EA201890171A1 (ru) Слитые белки btla агонисты и их применение
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.